about
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.A model of toxic neuropathy in Drosophila reveals a role for MORN4 in promoting axonal degenerationRepurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors.Propranolol therapy for infantile hemangioma: our experience.Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice.Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer.Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease.Azithromycin synergistically enhances anti-proliferative activity of vincristine in cervical and gastric cancer cells.Neuropathic pain during treatment for childhood acute lymphoblastic leukemia.Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia.Pharmacological therapies for infantile hemangiomas: A clinical study in 853 consecutive patients using a standard treatment algorithmAdverse interactions between antifungal azoles and vincristine: review and analysis of cases.The two faces of FBW7 in cancer drug resistance.Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma.Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology GroupAfter the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood.The impact of recent vincristine on human hematopoietic progenitor cell collection in pediatric patients with central nervous system tumors.Vincristine sulfate liposomal injection for acute lymphoblastic leukemia.Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma.Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia.An overlooked complication of vancomycin induced acute flaccid paralysis in a child with acute leukemia: a case report.Novel analogs of allopregnanolone show improved efficiency and specificity in neuroprotection and stimulation of proliferation.Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application.Severe neurological disorders and refractory aspergillosis in an adolescent treated by vincristine and voriconazole.Syndrome of inappropriate antidiuretic hormone secretion from concomitant use of itraconazole and vindesine.
P2860
Q30366990-35186B2F-4794-4510-8791-3D29BF1CE1F9Q33112264-AA9F6BCD-4365-4B63-8779-60AC1954921BQ33599587-46EBE98F-7DA2-4E97-81EF-D55FE4E93E4FQ33673881-538E541D-4993-4496-869D-4D46A52241BDQ33767004-5CC7E2C5-7A19-440F-951B-52FEC99156CBQ33882801-E8FB7384-6B13-49B8-BE9E-696CEEDE96B4Q34769640-6CF990BE-B10E-4FDB-BFBF-3187088E1ADDQ35038110-10BA30C7-3E59-42A7-83AE-2BFF03E38AD7Q35106072-AA2DC7EE-F173-4008-8787-65110E491764Q35754431-EA679896-FC90-450B-A3F2-AF01DB6B4715Q35923763-D3349CF3-6874-43FA-9718-4460ECF59795Q35936943-4CAB41AB-F34B-4630-BA10-DD8A1AADA819Q35999467-8C0BAD56-875F-441B-9977-8576F673BA23Q36028416-6ECF60E8-AA47-4DEA-9A46-1CFB47ED0904Q36306185-1ADDEBB0-8C42-4924-A0CF-BF646418DEC0Q36778333-384F160B-9551-4CE4-8971-031136C82B9AQ37138616-452C1FF1-CEBF-4932-AA08-62F7060EF029Q37305758-4A19341B-4F80-4691-9CE9-D9A6579244F2Q37832214-6FB31D69-A567-4171-9EF4-A134D6917EDAQ38063197-82E652CF-6701-4BCB-8C96-C8BC4293D6CAQ38683958-ED2FA6F2-6B5B-4CD2-A335-15C7739B6D4EQ47424155-69DEBDB6-DE6F-40BA-8335-999F0E22B044Q47729970-CEA84083-2535-40B5-9983-527CF6D2EE7EQ53117928-F2347356-538C-4FDF-B0B6-F559DB5AEABBQ53123208-BB4BF4AF-CB6A-4663-9CC9-033440BE8DE8
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vincristine: Can its therapeutic index be enhanced?
@en
Vincristine: Can its therapeutic index be enhanced?
@nl
type
label
Vincristine: Can its therapeutic index be enhanced?
@en
Vincristine: Can its therapeutic index be enhanced?
@nl
prefLabel
Vincristine: Can its therapeutic index be enhanced?
@en
Vincristine: Can its therapeutic index be enhanced?
@nl
P2860
P356
P1476
Vincristine: Can its therapeutic index be enhanced?
@en
P2093
Ross Pinkerton
P2860
P304
P356
10.1002/PBC.22161
P577
2009-12-01T00:00:00Z